ALS treatment PrimeC slows disease progression by 36% phase 2b trial results show 02-Jul-2024 By Clara Rodriguez Fernandez NeuroSense Therapeutics has announced positive phase 2b results for a drug combination designed to treat amyotrophic lateral sclerosis (ALS).